Spots Global Cancer Trial Database for A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
Official Title: A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
Study ID: NCT00212108
Conditions
Interventions
Study Description
Brief Summary: EGFR and COX-2 are involved in tumorigenesis, angiogenesis and metastases and are frequently over expressed in NPC.COX-2 and EGFR inhibitors are active in NPC.There is synergistic action between COX-2 and EGFR inhibitors. Study hypothesis: Celecoxib and gefitinib can reduce angiogenesis and induce anti-tumorigenicity in patients with nasopharngeal cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National University Hospital, Singapore, , Singapore
Contact Details
Name: Ross Soo, MD
Affiliation: National University Hospital, Singapore
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
